Back to Stocks

CMPX

Compass Therapeutics, Inc.
7 filings tracked
healthcarebiotechnologySMALL ($300M-2B)

Company Intelligence Hub

Filing history, signal momentum, and bull/bear evolution

Chronological Filing Evolution (Click to filter / toggle)

Thesis (Bull Case Evolution)

Compass Therapeutics is transitioning from a speculative clinical-stage entity to a near-commercial contender.…

Bullish Outlook

Antithesis (Bear Case / Structural Risks)

Despite the optimistic clinical headlines, the underlying data for tovecimig reveals significant fragility.…

Risk Factors

Read the full bull/bear analysis

You are reading the free preview. Start a free trial to unlock the complete bull & bear analysis for every CMPX filing.

Start Free Trial

Synthesis (Verdict & Resolution)

The latest 10-Q filing paints a picture of a company at a critical inflection point, balancing high-impact clinical success against the inherent volatility of biotech funding. The primary tension for investors lies in the interpretation of the tovecimig data: whether the PFS benefit is a definitive signal of efficacy or a fragile result skewed by crossover effects. While the balance sheet provides a necessary buffer, the increasing reliance on stock-based compensation highlights the cost of maintaining a high-talent research organization. Ultimately, the filing underscores a shift in risk profile. The company has successfully navigated the early clinical hurdles and now faces the more rigorous demands of BLA preparation and manufacturing scale-up. The outcome of the upcoming FDA meetings will likely be the primary driver of valuation, as it will determine if the current data package is sufficient for a successful market entry or if further, more expensive trials are required.

Selected Quarter

Core Takeaway

Compass has a viable lead candidate and sufficient cash for two years, but clinical data nuances and dilution risks remain.

Investor Lens

The trade-off between a high-conviction clinical win and the risk of statistical fragility in a small niche market.

Watch Next

Outcome of the pre-BLA meeting with the FDA regarding tovecimig data.

View Full SEC Report

Signal Momentum Chart

Quarterly net bull/bear signal ratio. Click nodes to select a quarter.

BULLISH (+1.0)NEUTRAL (0.0)BEARISH (-1.0)-0.07Q2 '26 (10-Q)

Signal Timeline

Active Filters:Quarter: Q2 '26 (10-Q)
bullishMay 5

Positive Phase 2/3 data and Orphan Drug Designation support a planned BLA submission.

guidance raise
80%
bearishMay 5

G&A expenses increased 41% YoY, primarily driven by stock-based compensation.

margin compression
40%
bearishMay 5

Significant amount of outstanding options and RSUs pose a future dilution threat.

dilution risk
60%
bullishMay 5

Positive Phase 2/3 data and Orphan Drug Designation support a planned BLA submission.

guidance raise
80%
bearishMay 5

G&A expenses increased 41% YoY, primarily driven by stock-based compensation.

margin compression
40%
bearishMay 5

Significant amount of outstanding options and RSUs pose a future dilution threat.

dilution risk
60%
bullishMay 5

Positive Phase 2/3 data and Orphan Drug Designation support a planned BLA submission.

guidance raise
80%
bearishMay 5

G&A expenses increased 41% YoY, primarily driven by stock-based compensation.

margin compression
40%
bearishMay 5

Significant amount of outstanding options and RSUs pose a future dilution threat.

dilution risk
60%
bullishMay 5

Positive Phase 2/3 data and Orphan Drug Designation support a planned BLA submission.

guidance raise
80%
bearishMay 5

G&A expenses increased 41% YoY, primarily driven by stock-based compensation.

margin compression
40%
bearishMay 5

Significant amount of outstanding options and RSUs pose a future dilution threat.

dilution risk
60%
bullishMay 5

Positive Phase 2/3 data and Orphan Drug Designation support a planned BLA submission.

guidance raise
80%
bearishMay 5

G&A expenses increased 41% YoY, primarily driven by stock-based compensation.

margin compression
40%
bearishMay 5

Significant amount of outstanding options and RSUs pose a future dilution threat.

dilution risk
60%
bullishMay 5

Positive Phase 2/3 data and Orphan Drug Designation support a planned BLA submission.

guidance raise
80%
bearishMay 5

G&A expenses increased 41% YoY, primarily driven by stock-based compensation.

margin compression
40%
bearishMay 5

Significant amount of outstanding options and RSUs pose a future dilution threat.

dilution risk
60%
bullishMay 5

Positive Phase 2/3 data and Orphan Drug Designation support a planned BLA submission.

guidance raise
80%
bearishMay 5

G&A expenses increased 41% YoY, primarily driven by stock-based compensation.

margin compression
40%
bearishMay 5

Significant amount of outstanding options and RSUs pose a future dilution threat.

dilution risk
60%

Filing History

10-QMay 5, 2026
Expand Sequence

The latest 10-Q filing paints a picture of a company at a critical inflection point, balancing high-impact clinical success against the inherent volatility of biotech funding. The primary tension for investors lies in the interpretation of the tovecimig data: whether the PFS benefit is a definitive signal of efficacy or a fragile result skewed by crossover effects. While the balance sheet provides a necessary buffer, the increasing reliance on stock-based compensation highlights the cost of maintaining a high-talent research organization. Ultimately, the filing underscores a shift in risk profile. The company has successfully navigated the early clinical hurdles and now faces the more rigorous demands of BLA preparation and manufacturing scale-up. The outcome of the upcoming FDA meetings will likely be the primary driver of valuation, as it will determine if the current data package is sufficient for a successful market entry or if further, more expensive trials are required.

Disclaimer: The synthesis provided is generated by AI models and should not be construed as investment advice. Analysis is based solely on regulatory data present at the time of publication. Consult a financial advisor for specific investment strategies.